Core Viewpoint - China Tongru (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," involving Yuanzi Gaoke Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a five-year survival rate of less than 50% [1] - The project focuses on addressing the challenges posed by neuroblastoma, which is referred to as the "king of childhood cancers," and aims to contribute to public health in China [1] Group 2: Technological Achievements - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, creating a "multimodal, low-dose, short-duration" precision diagnosis and treatment system for neuroblastoma [1] - Yuanzi Gaoke has developed the positron-emitting radiopharmaceutical sodium fluoride [18F] injection, completed Phase III clinical trials, and successfully registered it, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has also led the development of the iodine [123I] sodium solution radiopharmaceutical group standard and collaborated with the Friendship Hospital to provide a basis for standardized production of domestic radiopharmaceuticals [2] Group 3: Strategic Collaboration - Yuanzi Gaoke and the nuclear medicine department of the Friendship Hospital have established a long-term strategic partnership based on the concept of "industry-university-research-medical collaboration" [2] - The collaboration has resulted in significant advancements in radiopharmaceutical supply, research platform construction, and clinical trial promotion [2] - Moving forward, Yuanzi Gaoke will continue to focus on the field of nuclear medicine, increase investment in radiopharmaceutical research and technological innovation, and deepen cooperation with clinical institutions to enhance precision medical development [2]

（股份代號：1763） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於其他海外監管市場發佈的公告 公司附屬公司榮獲北京醫學科技獎一等獎 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年12月15日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司關於參與「兒童神經母細胞 瘤多模態核醫學分子影像體系的建立」項目榮獲北京醫學科技獎一等獎的公告」， 僅供參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年12月15日 於 ...